UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
(Exact name of Registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address of principal executive offices)
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading symbol(s) |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On January 24, 2024, the Non-Employee Director Compensation Program of CymaBay Therapeutics, Inc. was amended to change the value of equity provided to Directors on an annual basis to an award valued at approximately $250,000 and the value of equity provided to newly hired Directors to an award valued at approximately $400,000. Attached as Exhibit 10.1 is a summary of the revised Non-Employee Director Compensation Program, which became effective on January 1, 2024.
On January 24, 2024, Daniel Menold ceased to be the principal accounting officer of CymaBay and Harish Shantharam became the principal accounting officer in addition to his role as principal financial officer and Chief Financial Officer. Mr. Menold continues to be an employee of CymaBay.
Item 9.01. | Financial Statements and Exhibits. |
Exhibit No. |
Description | |
10.1 | Non-Employee Director Compensation Program. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CymaBay Therapeutics, Inc. | ||
By: | /s/ Paul Quinlan | |
Name: | Paul Quinlan | |
Title: | General Counsel |
Dated: January 26, 2024